RE-021 (Sparsentan) + Irbesartan
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focal Segmental Glomerulosclerosis
Conditions
Focal Segmental Glomerulosclerosis
Trial Timeline
Mar 1, 2014 → Mar 25, 2024
NCT ID
NCT01613118About RE-021 (Sparsentan) + Irbesartan
RE-021 (Sparsentan) + Irbesartan is a phase 2 stage product being developed by Travere Therapeutics for Focal Segmental Glomerulosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01613118. Target conditions include Focal Segmental Glomerulosclerosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01613118 | Phase 2 | Completed |
Competing Products
20 competing products in Focal Segmental Glomerulosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OnabotulinumtoxinA 145 UNT [Botox] | AbbVie | Approved | 85 |
| Dapagliflozin | AstraZeneca | Approved | 85 |
| Enfuvirtide + Tenofovir-Emtricitabine | Roche | Phase 2 | 52 |
| CCX140-B | Amgen | Phase 2 | 51 |
| PF-06730512 | Pfizer | Phase 2 | 51 |
| Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide | Pfizer | Approved | 84 |
| VX-147 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-147 | Vertex Pharmaceuticals | Phase 1 | 32 |
| IXP | Vertex Pharmaceuticals | Phase 1 | 32 |
| fresolimumab + fresolimumab + Placebo | Sanofi | Phase 2 | 51 |
| GC1008 + GC1008 + GC1008 + GC1008 | Sanofi | Phase 1 | 32 |
| frexalimab + brivekimig + rilzabrutinib + placebo | Sanofi | Phase 2 | 51 |
| Vivaglobin | CSL | Phase 2 | 51 |
| UCB0942 | UCB | Phase 2 | 49 |
| Levetiracetam + Carbamazepine + Lamotrigine | UCB | Approved | 82 |
| Brivaracetam + Brivaracetam | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Phase 2 | 49 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Pre-clinical | 20 |
| ARGX-117 | Argenx | Phase 2 | 49 |